The stopping of production scheduled for 2022
“In 2022, the company responsible for the production of cynomel for Sanofi announced its intention to stop this activity. A safety stock has been produced to anticipate production stopping. This stock will supply the French market until October 2025, ”said Sanofi. “To ensure the continuity of patient treatment”, the laboratory has undertaken to import alternative treatment into France, Thybon 20 Henning (Liothyronine Chlorhydrate), authorized in Germany for more than 25 years, underlines the ANSM.
These imports will take effect as soon as the cynomel is stopped marketing and will be followed by an authorization to marketing the Thybon, in order to “ensure lasting access to this medication” and “to prevent patients with repeated drug changes”.
“There will thus be no supply break between the end of Cynomel distribution and the start of the provision of Thybon,” says the ANSM.
The two drugs have the same basic molecule (Lithyronine), but different excipients.
